<p>Squarepoint Ops LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Kymera Therapeutics, Inc.（NASDAQ:KYMR - 免费报告）中的持仓减少了 32.3%。该机构投资者在该期间出售了 15,865 股后，持有 33,324 股公司的股票。根据其最近的 SEC 文件，Squarepoint Ops LLC 在 Kymera Therapeutics 的持股价值为 1,454,000 美元。</p>
<p>获取 <strong>Kymera Therapeutics</strong> 的提醒：</p>
<ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
<p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Farther Finance Advisors LLC 在第二季度将其在 Kymera Therapeutics 的持股增加了 642.9%。Farther Finance Advisors LLC 现在拥有 624 股公司股票，价值 27,000 美元，此前在该期间又购买了 540 股。PNC Financial Services Group Inc. 在第二季度将其在 Kymera Therapeutics 的股份增加了 506.6%。PNC Financial Services Group Inc. 现在拥有 922 股公司股票，价值 40,000 美元，此前又收购了 770 股。Raymond James Financial Inc. 在第二季度购买了 Kymera Therapeutics 的新头寸，价值 73,000 美元。Mirae Asset Global Investments Co. Ltd. 在第二季度将其在 Kymera Therapeutics 的持股增加了 15.8%。Mirae Asset Global Investments Co. Ltd. 现在拥有 2,516 股公司股票，价值 110,000 美元，此前在上个季度又收购了 343 股。最后，Lazard Asset Management LLC 在第二季度购买了价值 116,000 美元的 Kymera Therapeutics 新股份。</p>
<h2>Kymera Therapeutics 的内部交易</h2>
<p>在其他新闻中，董事 Jeffrey W. Albers 于 12 月 8 日星期一出售了 5,000 股公司的股票。股票以平均价格 89.76 美元出售，总价值 448,800.00 美元。该交易在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。此外，内部人士 Jared Gollob 于 12 月 8 日星期一出售了 49,307 股股票。该股票以平均价格 88.67 美元出售，总交易额为 4,372,051.69 美元。交易后，内部人士直接持有 109,992 股公司股票，价值 9,752,990.64 美元。此次交易使其持仓减少了 30.95%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士共出售了价值 41,408,199 美元的 488,585 股公司股票。目前，16.01% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师的看法</h2>
<p>几位研究分析师对该公司进行了评论。B. Riley 在 10 月 24 日的研究报告中将 Kymera Therapeutics 的目标价格从 60.00 美元上调至 80.00 美元，并给予该公司 &#34;买入&#34; 评级。瑞银集团在 12 月 4 日的报告中将 Kymera Therapeutics 的评级上调至 &#34;强力买入&#34;。BTIG Research 在 12 月 8 日的研究报告中为 Kymera Therapeutics 设置了 138.00 美元的目标价格。花旗集团在 12 月 9 日的研究报告中将 Kymera Therapeutics 的目标价格从 80.00 美元上调至 110.00 美元，并给予该公司 &#34;买入&#34; 评级。最后，Stephens 在 12 月 11 日的研究报告中将 Kymera Therapeutics 的目标价格从 65.00 美元上调至 110.00 美元，并给予该公司 &#34;增持&#34; 评级。两位股票研究分析师对该股票给予了强力买入评级，十九位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;买入&#34;，共识目标价格为 114.45 美元。</p>
<p><strong>查看我们对 Kymera Therapeutics 的最新股票分析</strong></p>
<h2>Kymera Therapeutics 股票上涨 5.5%</h2>
<p>NASDAQ KYMR 的股票在周五开盘时为 83.99 美元。Kymera Therapeutics, Inc. 的 52 周低点为 19.44 美元，52 周高点为 103.00 美元。该公司的 50 日移动平均价格为 67.39 美元，200 日移动平均价格为 53.63 美元。该公司的市值为 60.4 亿美元，市盈率为 -23.40，贝塔系数为 2.28。</p>
<p>Kymera Therapeutics（NASDAQ:KYMR - 获取免费报告）最近于 11 月 4 日宣布了其财报。该公司报告的每股收益（EPS）为（0.90）美元，低于分析师的共识预期（0.71）美元，差距为（0.19）美元。Kymera Therapeutics 的净利润率为 -674.81%，股本回报率为 -32.92%。该公司在该季度的收入为 276 万美元，而分析师预期为 2315 万美元。分析师预计 Kymera Therapeutics, Inc. 本年度的每股收益将为 -2.79。</p>
<h2>Kymera Therapeutics 简介</h2>
<p>（免费报告）</p>
<p>Kymera Therapeutics, Inc. 是一家临床阶段的生物制药公司，总部位于马萨诸塞州沃特敦，专注于发现、开发和商业化利用身体自然蛋白质稳态通路的小分子疗法。自 2016 年成立以来，Kymera 一直致力于一种靶向蛋白降解平台，旨在识别和选择性消除致病蛋白。该公司的专有 Pegasus™ 平台结合了来自泛素生物学和药物化学的见解，以推动在多个治疗领域的创新降解剂候选药物的进展。</p>
<p>该公司的产品管线强调免疫学和肿瘤学。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Kymera Therapeutics</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>耐克财报超预期，但在中国市场面临挑战并遭遇关税</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>2026 年的四只高潜力 ETF：小型股、太空股票等</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Kymera Therapeutics 吗？</h2>
<p>在考虑 Kymera Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Kymera Therapeutics 并不在名单上。</p>
<p>虽然 Kymera Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KYMR

<p>Squarepoint Ops LLC 在第二季度减少了对 Kymera Therapeutics 的持股比例，降幅为 32.3%。尽管如此，几位分析师仍然给予 Kymera “买入” 或 “强力买入” 的评级，目标价格范围在 80 美元到 138 美元之间。该股票的共识目标价格为 114.45 美元，最近上涨了 5.5%，达到了 83.99 美元。还注意到了一些内部交易和其他机构投资</p>

<p>Squarepoint Ops LLC reduced its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 32.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,324 shares of the company's stock after selling 15,865 shares during the period. Squarepoint Ops LLC's holdings in Kymera Therapeutics were worth $1,454,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Squarepoint Ops LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第二季度将其在 Kymera Therapeutics, Inc.（NASDAQ:KYMR - 免费报告）中的持仓减少了 32.3%。该机构投资者在该期间出售了 15,865 股后，持有 33,324 股公司的股票。根据其最近的 SEC 文件，Squarepoint Ops LLC 在 Kymera Therapeutics 的持股价值为 1,454,000 美元。</p>
</div><p>Get <strong>Kymera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kymera Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师对这些鲜为人知的生物制药股票赞不绝口</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently bought and sold shares of the company. Farther Finance Advisors LLC raised its holdings in Kymera Therapeutics by 642.9% in the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock valued at $27,000 after buying an additional 540 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Kymera Therapeutics by 506.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock valued at $40,000 after acquiring an additional 770 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Kymera Therapeutics in the 2nd quarter valued at $73,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Kymera Therapeutics by 15.8% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company's stock valued at $110,000 after acquiring an additional 343 shares in the last quarter. Finally, Lazard Asset Management LLC purchased a new stake in Kymera Therapeutics during the 2nd quarter worth $116,000.</p>
<div class="lb-trans"><p>其他机构投资者和对冲基金最近也买卖了该公司的股票。Farther Finance Advisors LLC 在第二季度将其在 Kymera Therapeutics 的持股增加了 642.9%。Farther Finance Advisors LLC 现在拥有 624 股公司股票，价值 27,000 美元，此前在该期间又购买了 540 股。PNC Financial Services Group Inc. 在第二季度将其在 Kymera Therapeutics 的股份增加了 506.6%。PNC Financial Services Group Inc. 现在拥有 922 股公司股票，价值 40,000 美元，此前又收购了 770 股。Raymond James Financial Inc. 在第二季度购买了 Kymera Therapeutics 的新头寸，价值 73,000 美元。Mirae Asset Global Investments Co. Ltd. 在第二季度将其在 Kymera Therapeutics 的持股增加了 15.8%。Mirae Asset Global Investments Co. Ltd. 现在拥有 2,516 股公司股票，价值 110,000 美元，此前在上个季度又收购了 343 股。最后，Lazard Asset Management LLC 在第二季度购买了价值 116,000 美元的 Kymera Therapeutics 新股份。</p>
</div><h2>Insider Transactions at Kymera Therapeutics</h2>
<div class="lb-trans"><h2>Kymera Therapeutics 的内部交易</h2>
</div><p>In other news, Director Jeffrey W. Albers sold 5,000 shares of the company's stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jared Gollob sold 49,307 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the transaction, the insider directly owned 109,992 shares in the company, valued at $9,752,990.64. The trade was a 30.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 488,585 shares of company stock valued at $41,408,199 over the last ninety days. 16.01% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Jeffrey W. Albers 于 12 月 8 日星期一出售了 5,000 股公司的股票。股票以平均价格 89.76 美元出售，总价值 448,800.00 美元。该交易在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。此外，内部人士 Jared Gollob 于 12 月 8 日星期一出售了 49,307 股股票。该股票以平均价格 88.67 美元出售，总交易额为 4,372,051.69 美元。交易后，内部人士直接持有 109,992 股公司股票，价值 9,752,990.64 美元。此次交易使其持仓减少了 30.95%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去的九十天里，内部人士共出售了价值 41,408,199 美元的 488,585 股公司股票。目前，16.01% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>Several research analysts have commented on the company. B. Riley raised their price objective on Kymera Therapeutics from $60.00 to $80.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, October 24th. UBS Group upgraded Kymera Therapeutics to a &#34;strong-buy&#34; rating in a report on Thursday, December 4th. BTIG Research set a $138.00 price target on Kymera Therapeutics in a research report on Monday, December 8th. Citigroup increased their price objective on shares of Kymera Therapeutics from $80.00 to $110.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, December 9th. Finally, Stephens lifted their price objective on shares of Kymera Therapeutics from $65.00 to $110.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of &#34;Buy&#34; and a consensus target price of $114.45.</p>
<div class="lb-trans"><p>几位研究分析师对该公司进行了评论。B. Riley 在 10 月 24 日的研究报告中将 Kymera Therapeutics 的目标价格从 60.00 美元上调至 80.00 美元，并给予该公司 &#34;买入&#34; 评级。瑞银集团在 12 月 4 日的报告中将 Kymera Therapeutics 的评级上调至 &#34;强力买入&#34;。BTIG Research 在 12 月 8 日的研究报告中为 Kymera Therapeutics 设置了 138.00 美元的目标价格。花旗集团在 12 月 9 日的研究报告中将 Kymera Therapeutics 的目标价格从 80.00 美元上调至 110.00 美元，并给予该公司 &#34;买入&#34; 评级。最后，Stephens 在 12 月 11 日的研究报告中将 Kymera Therapeutics 的目标价格从 65.00 美元上调至 110.00 美元，并给予该公司 &#34;增持&#34; 评级。两位股票研究分析师对该股票给予了强力买入评级，十九位分析师给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;买入&#34;，共识目标价格为 114.45 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Kymera Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Kymera Therapeutics 的最新股票分析</strong></p>
</div><h2>Kymera Therapeutics Stock Up 5.5%</h2>
<div class="lb-trans"><h2>Kymera Therapeutics 股票上涨 5.5%</h2>
</div><p>Shares of NASDAQ KYMR opened at $83.99 on Friday. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The business has a 50 day moving average price of $67.39 and a two-hundred day moving average price of $53.63. The firm has a market cap of $6.04 billion, a PE ratio of -23.40 and a beta of 2.28.</p>
<div class="lb-trans"><p>NASDAQ KYMR 的股票在周五开盘时为 83.99 美元。Kymera Therapeutics, Inc. 的 52 周低点为 19.44 美元，52 周高点为 103.00 美元。该公司的 50 日移动平均价格为 67.39 美元，200 日移动平均价格为 53.63 美元。该公司的市值为 60.4 亿美元，市盈率为 -23.40，贝塔系数为 2.28。</p>
</div><p>Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The business had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million. On average, analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.</p>
<div class="lb-trans"><p>Kymera Therapeutics（NASDAQ:KYMR - 获取免费报告）最近于 11 月 4 日宣布了其财报。该公司报告的每股收益（EPS）为（0.90）美元，低于分析师的共识预期（0.71）美元，差距为（0.19）美元。Kymera Therapeutics 的净利润率为 -674.81%，股本回报率为 -32.92%。该公司在该季度的收入为 276 万美元，而分析师预期为 2315 万美元。分析师预计 Kymera Therapeutics, Inc. 本年度的每股收益将为 -2.79。</p>
</div><h2>Kymera Therapeutics Profile</h2>
<div class="lb-trans"><h2>Kymera Therapeutics 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.</p>
<div class="lb-trans"><p>Kymera Therapeutics, Inc. 是一家临床阶段的生物制药公司，总部位于马萨诸塞州沃特敦，专注于发现、开发和商业化利用身体自然蛋白质稳态通路的小分子疗法。自 2016 年成立以来，Kymera 一直致力于一种靶向蛋白降解平台，旨在识别和选择性消除致病蛋白。该公司的专有 Pegasus™ 平台结合了来自泛素生物学和药物化学的见解，以推动在多个治疗领域的创新降解剂候选药物的进展。</p>
</div><p>The company's pipeline emphasizes immunology and oncology.</p>
<div class="lb-trans"><p>该公司的产品管线强调免疫学和肿瘤学。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Kymera Therapeutics</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Kymera Therapeutics</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>耐克财报超预期，但在中国市场面临挑战并遭遇关税</li>
<li>最活跃的股票：美元交易量与股票交易量</li>
<li>人工智能热潮是泡沫吗？这两只分红股票说不是</li>
<li>股票分红削减发生，你准备好了吗？</li>
<li>2026 年的四只高潜力 ETF：小型股、太空股票等</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1lNUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=KYMR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Kymera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kymera Therapeutics 吗？</h2>
</div><p>Before you consider Kymera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kymera Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Kymera Therapeutics 并不在名单上。</p>
</div><p>While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kymera Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Squarepoint Ops LLC 减少了其在 Kymera Therapeutics, Inc. $KYMR 的持仓